Endocrine therapy (ET) targeting estrogen receptor (ER) signaling is still the mainstay treatment option for early or advanced ER-positive breast cancer (BC) and may involve suppressing estrogen production by means of aromatase inhibitors or directly blocking the ER pathway through selective estrogen receptor modulators such as tamoxifen or selective estrogen receptor degraders such as fulvestrant. However, despite the availability of this armamentarium in clinical practice, de novo or acquired resistance to ET is the main cause of endocrine-based treatment failure leading to the progression of the BC. Recent advances in targeting, modulating, and degrading ERs have led to the development of new drugs capable of overcoming intrinsic or acquired ET resistance related to alterations in the ESR1 gene. The new oral selective estrogen receptor degraders, which are capable of reducing ER protein expression and blocking estrogen-dependent and-independent ER signaling, have a broader spectrum of activity against ESR1 mutations and seem to be a promising means of overcoming the failure of standard ET. The aim of this review is to summarize the development of oral selective estrogen receptor degraders, their current status, and their future perspectives.(c) 2023 Elsevier Inc. All rights reserved.

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? / Ferro, A.; Generali, D.; Caffo, O.; Caldara, A.; De Lisi, D.; Dipasquale, M.; Lorenzi, M.; Monteverdi, S.; Fedele, P.; Ciribilli, Y.. - In: SEMINARS IN ONCOLOGY. - ISSN 0093-7754. - 50:3-5(2023), pp. 90-101. [10.1053/j.seminoncol.2023.08.002]

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Ferro A.
;
Generali D.;Caffo O.;Caldara A.;Lorenzi M.;Fedele P.;Ciribilli Y.
2023-01-01

Abstract

Endocrine therapy (ET) targeting estrogen receptor (ER) signaling is still the mainstay treatment option for early or advanced ER-positive breast cancer (BC) and may involve suppressing estrogen production by means of aromatase inhibitors or directly blocking the ER pathway through selective estrogen receptor modulators such as tamoxifen or selective estrogen receptor degraders such as fulvestrant. However, despite the availability of this armamentarium in clinical practice, de novo or acquired resistance to ET is the main cause of endocrine-based treatment failure leading to the progression of the BC. Recent advances in targeting, modulating, and degrading ERs have led to the development of new drugs capable of overcoming intrinsic or acquired ET resistance related to alterations in the ESR1 gene. The new oral selective estrogen receptor degraders, which are capable of reducing ER protein expression and blocking estrogen-dependent and-independent ER signaling, have a broader spectrum of activity against ESR1 mutations and seem to be a promising means of overcoming the failure of standard ET. The aim of this review is to summarize the development of oral selective estrogen receptor degraders, their current status, and their future perspectives.(c) 2023 Elsevier Inc. All rights reserved.
2023
Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, Lorenzi M, Monteverdi S, Fedele P, Ciribilli Y.
Ferro, A.; Generali, D.; Caffo, O.; Caldara, A.; De Lisi, D.; Dipasquale, M.; Lorenzi, M.; Monteverdi, S.; Fedele, P.; Ciribilli, Y.
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? / Ferro, A.; Generali, D.; Caffo, O.; Caldara, A.; De Lisi, D.; Dipasquale, M.; Lorenzi, M.; Monteverdi, S.; Fedele, P.; Ciribilli, Y.. - In: SEMINARS IN ONCOLOGY. - ISSN 0093-7754. - 50:3-5(2023), pp. 90-101. [10.1053/j.seminoncol.2023.08.002]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/437817
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
  • OpenAlex ND
social impact